VRDNViridian Therapeutics, Inc.
$18.67-3.9% 1Y
$18.67
$13.3052 weeks$33.78
Is the business good?
Watch
1 to watch, 3 without dataMargins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years−3599.5 ptsderived
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is VRDN?
Viridian Therapeutics, Inc. keeps −570% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
−570%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- R&D as % of revenue
- 456%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −10512% |
| FY2021 | −2691% |
| FY2022 | −7579% |
| FY2023 | −81035% |
| FY2024 | −99018% |
| FY2025 | −513% |
Details›
- Operating margin12 months to Q2 2026
- −570%
- Net margin12 months to Q2 2026
- −544%
- Free cash flow margin
- −471%
- R&D as % of revenue
- 456%
- Revenue, trailing twelve months
- $71M
- Free cash flow, trailing twelve months
- −$335M
- Net income, trailing twelve months
- −$387M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks